These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 7858534

  • 41. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
    Josting A, Kàtay I, Rueffer U, Winter S, Tesch H, Engert A, Diehl V, Wickramanayake PD.
    Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
    [Abstract] [Full Text] [Related]

  • 42. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F.
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [Abstract] [Full Text] [Related]

  • 43. High-dose etoposide and cisplatin in refractory or recurrent non-Hodgkin's lymphomas (NHL).
    Colombat P, Biron P, Patte C, Harousseau JL, Demeocq F, Benz-Lemoine E, Frappaz D, Lamagnère JP, Philip T.
    Nouv Rev Fr Hematol (1978); 1990 Feb; 32(3):183-6. PubMed ID: 2216702
    [Abstract] [Full Text] [Related]

  • 44. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
    Vaughan WP, Kris E, Vose J, Bierman PJ, Gwilt P, Armitage JO.
    J Clin Oncol; 1995 May; 13(5):1089-95. PubMed ID: 7738614
    [Abstract] [Full Text] [Related]

  • 45. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients).
    Philip T, Chauvin F, Bron D, Guglielmi C, Hagenbeek A, Coiffier B, Gisselbrecht C, Kluin Nelemans JC, Somers R, Misset JC.
    Ann Oncol; 1991 Jan; 2 Suppl 1():57-64. PubMed ID: 2043500
    [Abstract] [Full Text] [Related]

  • 46. [Autologous bone marrow transfusion in the treatment of adults with hematologic neoplasms. Experiences from Bern].
    Brun del Re GP, Tschopp L, Cerny T, Bucher U.
    Schweiz Med Wochenschr; 1989 Jun 24; 119(25):902-10. PubMed ID: 2667130
    [Abstract] [Full Text] [Related]

  • 47. Diffuse large cell non-Hodgkin's lymphoma: results of M-BACOD combination chemotherapy.
    Polliack A, Uziely B, Isacson R, Lugassy G, Rochlemer S, Gez E, Libson E, Sulkes A, Weshler Z.
    Isr J Med Sci; 1988 Jun 24; 24(9-10):619-22. PubMed ID: 2462553
    [Abstract] [Full Text] [Related]

  • 48. High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease.
    Ahmed T, Ciavarella D, Feldman E, Ascensao J, Hussain F, Engelking C, Gingrich S, Mittelman A, Coleman M, Arlin ZA.
    Leukemia; 1989 Jan 24; 3(1):19-22. PubMed ID: 2642573
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP, Herzig GP, Herzig RH, Klingemann HG, LeMaistre CF.
    J Clin Oncol; 1991 Oct 24; 9(10):1871-9. PubMed ID: 1919637
    [Abstract] [Full Text] [Related]

  • 51. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
    Zander AR, Vellekoop L, Spitzer G, Verma DS, Litam J, McCredie KB, Keating M, Hester JP, Dicke KA.
    Cancer Treat Rep; 1981 Oct 24; 65(5-6):377-81. PubMed ID: 7016323
    [Abstract] [Full Text] [Related]

  • 52. [ABEP chemotherapy in the treatment of advanced non-Hodgkin's lymphomas].
    Yoshida T, Nakanishi J, Ito K, Kobayashi K, Ohtake S, Nakamura S, Matsuda T, Nakagoshi T, Natori K, Nakamura E.
    Gan To Kagaku Ryoho; 1986 Apr 24; 13(4 Pt 1):984-9. PubMed ID: 3963862
    [Abstract] [Full Text] [Related]

  • 53. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
    Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP.
    J Clin Oncol; 1993 Jun 24; 11(6):1085-91. PubMed ID: 8099120
    [Abstract] [Full Text] [Related]

  • 54. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors.
    Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottler-Fox M, Goldspiel B, Steinberg SM, Longo DL, Wittes RE.
    J Clin Oncol; 1992 Nov 24; 10(11):1712-22. PubMed ID: 1403054
    [Abstract] [Full Text] [Related]

  • 55. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
    Lu C, Braine HG, Kaizer H, Saral R, Tutschka PJ, Santos GW.
    Cancer Treat Rep; 1984 May 24; 68(5):711-7. PubMed ID: 6373004
    [Abstract] [Full Text] [Related]

  • 56. [High-dose cyclophosphamide, thio-TEPA, etoposide with autologous bone marrow transplantation for refractory cancers].
    Mukaiyama T, Ogawa M, Horikoshi N, Inoue K, Hirano A, Mizunuma N, Matsuoka A, Matsumura T.
    Gan To Kagaku Ryoho; 1990 Nov 24; 17(11):2207-11. PubMed ID: 2122810
    [Abstract] [Full Text] [Related]

  • 57. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
    Girouard C, Dufresne J, Imrie K, Stewart AK, Brandwein J, Prince HM, Pantolony D, Keating A, Crump M.
    Ann Oncol; 1997 Jul 24; 8(7):675-80. PubMed ID: 9296221
    [Abstract] [Full Text] [Related]

  • 58. The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients).
    Hagenbeek A, Philip T, Bron D, Guglielmi C, Coiffier B, Gisselbrecht C, Kluin Nelemans JC, Somers R, Misset JL, Van der Lely J.
    Bone Marrow Transplant; 1991 Jul 24; 7 Suppl 2():142. PubMed ID: 1878684
    [No Abstract] [Full Text] [Related]

  • 59. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology.
    Gentet JC, Patte C, Quintana E, Bergeron C, Rubie H, Pein F, Demaille MC, Philip T, Raybaud C.
    J Clin Oncol; 1990 Apr 24; 8(4):661-5. PubMed ID: 2313335
    [Abstract] [Full Text] [Related]

  • 60. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
    Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Kwak LW, Long GD, Stallbaum B, O'Connor P, Blume KG.
    Ann Oncol; 1991 Jan 24; 2 Suppl 1():47-50. PubMed ID: 2043498
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.